DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market" report to their offering.
"Pipeline Disruptors" - the innovative therapies that impact current therapies with significant competition and alter the course of treatment. For the purpose of this study, it may affect current therapies that were also considered disruptor innovations at one time or involves a new innovation that is expected to displace other treatments.
The pharmaceutical market is fluid and at times can defy predictions of observers of today's pipelines. In recent years, several 'disruptors' have hit the market and pushed aside the current standard treatment protocols.
Consider these Two Cases:
Gilead Sciences has turned the Hepatitis C (HCV) treatment market upside down, for its competitors at least. In 2013, Gilead began to rollout its new therapies for HCV, of which the company claimed were superior products to the established market. A bold claim considering it was going up against some of the biggest names in biopharmaceutical participation - mainly Merck and Roche. The market showed favor for Gilead's products, which began to erode sales for Merck and Roche's HCV products. By 2015, Gilead had a solid hold on the market with about 80% market share.
In December 2014, Bristol-Myers Squibb was granted approval for its PD-1 monoclonal antibody Opdivo (nivolumab). Opdivo was originally granted approval for advanced melanoma; by the end of 2016, lung cancer, renal cell carcinoma, lymphoma, and head & neck cancer were also approved. Approvals continue to be pursued and granted for 2017.
What will be the next source of disruption in the market?
This report covers market opportunities based on pipeline developments for six key therapeutic specialties:
- Alzheimer's Disease
- Breast Cancer
- Lung Cancer
Key Topics Covered:
1: Executive Summary
2: The Status Of The Global Biopharmaceutical Market Target Selection Process Increases In Importance Top R&D Spenders
3: Company Innovation Strategies: The Path To Pipeline Disruptor Innovation
4: Pipeline Disruptors: Alzheimer's Disease Market Opportunity
5: Pipeline Disruptors: Asthma
6: Pipeline Disruptors: Breast Cancer Market Opportunity
7: Pipeline Disruptors: Leukemia Market Opportunity
8: Pipeline Disruptors: Lung Cancer Market Opportunity
9: Pipeline Disruptors: Lymphoma Market Opportunity
10: Market Conclusions
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly & Company
- Gilead Science
- Johnson & Johnson
- Teva Pharmaceutical
For more information about this report visit http://www.researchandmarkets.com/research/4hlhd7/potential